每日一次奈他舒地尔与每日两次噻吗洛尔治疗眼压升高的随机3期ROCKET-4研究
ROCKET-4为双盲随机3期非劣效性研究,比较奈他舒地尔0.02%每日一次(QD)与噻吗洛尔0.5%每日两次(BID)在开角型青光眼或高眼压症患者中的降眼压疗效与安全性。主要疗效分析共纳入每组186例基线眼压<25 mmHg患者,奈他舒地尔QD在多个时间点达到对噻吗洛尔BID的非劣效性,降眼压效果持续6个月,未报告治疗相关严重不良事件,结膜充血为最常见眼部不良事件(47.9%)。
要点
- 奈他舒地尔QD在基线眼压<25 mmHg患者中降眼压效果非劣效于噻吗洛尔BID。
- 奈他舒地尔降眼压效果持续6个月,未报告治疗相关严重不良事件。
- 奈他舒地尔最常见眼部不良事件为结膜充血(47.9%),以轻度为主。
核心结论
- 奈他舒地尔0.02%每日一次(QD)在开角型青光眼或高眼压症患者中降眼压效果非劣效于噻吗洛尔0.5%每日两次(BID),且眼部不良事件可耐受。
研究设计与样本
- 双盲、随机、3期非劣效性研究,纳入开角型青光眼或高眼压症患者,未用药基线眼压8:00 AM时>20且<30 mmHg,随机接受奈他舒地尔0.02% QD(PM)或噻吗洛尔0.5% BID。
- 主要疗效分析为基线眼压<25 mmHg的符合方案人群,每组186例;安全性记录覆盖6个月治疗期。
主要发现
- 主要终点为第2周、第6周和第3个月8:00 AM、10:00 AM和4:00 PM的平均眼压,奈他舒地尔QD达到对噻吗洛尔BID的非劣效性。
- 奈他舒地尔平均治疗眼压范围为16.3至17.9 mmHg,噻吗洛尔为16.7至17.6 mmHg;相对基线平均降幅分别为3.9至4.7 mmHg和3.8至5.2 mmHg。
- 预设次要分析中,奈他舒地尔在基线眼压<27 mmHg和<30 mmHg患者中均显示对噻吗洛尔的非劣效性;降眼压效果持续6个月。
- 两种药物均未报告治疗相关严重不良事件;噻吗洛尔组在所有研究访视中记录到平均心率统计学显著降低。
- 奈他舒地尔治疗患者最常见眼部不良事件为结膜充血(47.9%),以轻度为主。
关键数值与推荐
- 非劣效性主要终点:第2周、第6周和第3个月多个时间点的平均眼压,奈他舒地尔QD满足对噻吗洛尔BID的非劣效性标准。
- 基线眼压<25 mmHg患者中,奈他舒地尔平均治疗眼压16.3至17.9 mmHg,噻吗洛尔16.7至17.6 mmHg。
- 奈他舒地尔组结膜充血发生率为47.9%,以轻度为主。
临床怎么用
- 对于开角型青光眼或高眼压症患者,奈他舒地尔每日一次(晚间)可作为噻吗洛尔每日两次的替代降眼压方案,需关注结膜充血等眼部不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil once daily (QD) and timolol twice daily (BID). DESIGN: Double-masked, randomized, phase 3, noninferiority study. METHODS: Patients with open-angle glaucoma or ocular hypertension (unmedicated baseline IOP >20 to <30 mm Hg at 8:00 AM) were randomized to netarsudil ophthalmic solution 0.02% QD (PM) or timolol ophthalmic solution 0.5% BID. The primary endpoint was mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and month 3 in patients with baseline IOP <25 mm Hg (per-protocol population). Safety was recorded over the 6-month treatment period. RESULTS: A total of 186 patients from each treatment arm were included in the primary efficacy analysis. Netarsudil QD met the criteria for noninferiority to timolol BID. Mean treated IOP ranged from 16.3 to 17.9 mm Hg for netarsudil and 16.7 to 17.6 for timolol, with mean reductions from baseline of 3.9 to 4.7 mm Hg and 3.8 to 5.2 mm Hg, respectively. In prespecified secondary analyses, netarsudil demonstrated noninferiority to timolol in patients with baseline IOP <27 mm Hg and <30 mm Hg. The IOP-lowering effects of netarsudil were sustained over 6 months of treatment. No treatment-related serious adverse event (AE) was reported for either study drug. However, statistically significant reductions in mean heart rate were recorded at all study visits for the timolol group. The most frequent ocular AE among netarsudil-treated patients was conjunctival hyperemia (47.9%), which was predominately mild. CONCLUSIONS: Netarsudil QD (PM), a first-in-class IOP-lowering medication, was noninferior to timolol BID and was associated with tolerable ocular AEs.
引用
- Khouri AS, Serle JB, Bacharach J, et al. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019. PMID: 30862500. doi:10.1016/j.ajo.2019.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。